Prognostic biomarkers in melanoma
Molecular profiling of small extracellular vesicles (sEV) isolated from plasma of cancer patients emerges as a promising strategy for biomarkers discovery. We investigated the proteomic profiles of melanoma cell-derived (MTEX) and non-malignant cell-derived (NMTEX) sEV using high-resolution mass spectrometry. Paired analysis identified the MTEX-associated profile of 16 proteins that discriminated MTEX from NMTEX. We also identified the MTEX profile that discriminated between patients with no evidence of melanoma (NED) after therapy and those with progressive disease (PD). This is the first report documenting that proteomes of tumour-derived sEV in patients’ plasma discriminate cancer from non-cancer and identify proteins with the potential to serve as prognostic biomarkers in melanoma.
More about the achievements of SUT researchers in the fight with cancer is available in the paper below:
